Australia Expands TRIKAFTA Reimbursement for Cystic Fibrosis

– With this reimbursement, approximately 45 people with cystic fibrosis in Australia will become eligible for a CFTR modulator for the first time –

– The expanded listing includes an additional 271 mutations, many of them rare –

Sydney, 24 June 2025 – Vertex Pharmaceuticals today announced that as of 1 July 2025, the funding of TRIKAFTA^® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) will be expanded on the Pharmaceutical Benefits Scheme (PBS) to include patients with cystic fibrosis aged 2 years and older who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is considered responsive to elexacaftor/tezacaftor/ivacaftor potentiation based on clinical or in vitro data.

CF is a life-shortening, genetic disease affecting approximately 3,800 people in Australia[i]. There are over 2,000 known CFTR gene mutations, about half of which cause cystic fibrosis[ii]. The expanded listing includes an additional 271 mutations as listed in the Australian Product Information and also allows patients that do not have two 'Class I' mutations to be treated[iii]. More than 90% of Australians living with cystic fibrosis now have access to a CFTR modulatorⁱ.

"Vertex has been committed to the cystic fibrosis Community for more than 20 years. Our goal has always been to ensure that all those who can benefit from our medicines get access as quickly as possible, no matter their age or genotype. This expanded PBS listing, which enables funded access to Trikafta for additional mutations, many of them ultra-rare, is testament to this and our uncompromising commitment to patients," said Sabrina Barbic, Senior Country Manager of Vertex Pharmaceuticals ANZ.

Australians with cystic fibrosis should speak with their clinician about the management of their condition.